Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers
Open Access
- 24 August 2012
- journal article
- pharmacokinetics and-disposition
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 69 (3), 489-497
- https://doi.org/10.1007/s00228-012-1373-8
Abstract
We performed a population pharmacokinetic analysis of phenytoin after intravenous administration of fosphenytoin sodium in healthy, neurosurgical, and epileptic subjects, including pediatric patients, and determined the optimal dose and infusion rate for achieving the therapeutic range. We used pooled data obtained from two phase I studies and one phase III study performed in Japan. The population pharmacokinetic analysis was performed using NONMEM software. The optimal dose and infusion rate were determined using simulation results obtained using the final model. The therapeutic range for total plasma phenytoin concentration is 10–20 μg/mL. We used a linear two-compartment model with conversion of fosphenytoin to phenytoin. Pharmacokinetic parameters of phenytoin, such as total clearance and central and peripheral volume of distribution were influenced by body weight. The dose simulations are as follows. In adult patients, the optimal dose and infusion rate of phenytoin for achieving the therapeutic range was 22.5 mg/kg and 3 mg/kg/min respectively. In pediatric patients, the total plasma concentration of phenytoin was within the therapeutic range for a shorter duration than that in adult patients at 22.5 mg/kg (3 mg/kg/min). However, many pediatric patients showed phenytoin concentration within the toxic range after administration of a dose of 30 mg/kg. The pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium could be described using a linear two-compartment model. The administration of fosphenytoin sodium 22.5 mg/kg at an infusion rate of 3 mg/kg/min was optimal for achieving the desired plasma phenytoin concentration.Keywords
This publication has 10 references indexed in Scilit:
- Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsyNeurology, 2008
- Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE MethodPharmaceutical Research, 2007
- Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approachJournal of Clinical Pharmacy & Therapeutics, 2006
- The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population PharmacokineticsEpilepsia, 1998
- Non-Steady State Population Kinetics of Intravenous PhenytoinTherapeutic Drug Monitoring, 1998
- Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy*Clinical Pharmacology & Therapeutics, 1997
- Stability and Performance of a Population Pharmacokinetic ModelThe Journal of Clinical Pharmacology, 1997
- Population Pharmacokinetics of Phenytoin in Japanese Patients with Epilepsy: Analysis with a Dose-Dependent Clearance Model.Biological & Pharmaceutical Bulletin, 1996
- Population pharmacokinetics of phenytoin from routine clinical data in Japan: An update.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990
- Phenytoin Prodrug 3-Phosphoryloxymethyl Phenytoin (ACC-9653): Pharmacokinetics in Patients following Intravenous and Intramuscular AdministrationJournal of Pharmaceutical Sciences, 1989